* Says mid-stage trial data shows increase in female libido
* Shares up 6 pct
June 30 (Reuters) - BioSante Pharmaceuticals Inc BPAX.O said data from a mid-stage trial of its oral contraceptive (OC) pill showed an increase in the frequency of sexual activity in women taking OC, sending its shares up 6 percent.
The company’s OC Pill-Plus is designed to restore testosterone levels that are significantly suppressed during OC use, BioSante said.
The company said the data from the trial also showed a reduction in frequency of rejection of initiation of sexual activity by partner.
Many women who use OCs have reduced sexual desire, arousabilty and sexual activity due to the effects of estrogen and progestogen in normal OCs, the company said.
BioSante is also developing a testosterone skin gel to treat a decline in libido in menopausal women.
Shares of the company were up 10 cents at $1.90 in pre-market trade. They closed at $1.80 Tuesday on Nasdaq. (Reporting by Anand Basu in Bangalore; Editing by Prem Udayabhanu)